Broad big health: covers prevention, treatment, rehabilitation, wellness, health management across all populations and life cycles.
Narrow definition: pharmaceuticals, medical devices, medical services. This white paper focuses on the narrow industrial chain and explores capital & financial services.

Dual attributes: commercial + public welfare.

2018 China pharmaceutical industry revenue: RMB 2.58 trillion.
Health service market: RMB 5.45 trillion.
Total approx RMB 8.03 trillion.

“Healthy China 2030” targets: 2020 → RMB 10 trillion.
2030 → exceed RMB 16 trillion.

Upstream: Pharmaceutical & medical device manufacturing (chemical drugs, biologics, TCM, devices).
Midstream: Pharmaceutical distribution (wholesale, logistics).
Downstream: Medical institutions, retail pharmacies, internet healthcare, physical examination centers.

Supporting roles:医保(medical insurance), commercial insurance, information platforms, financial leasing.

Aging population, rising sub-healthy groups, policy reforms (volume-based procurement, two-invoice system, internet healthcare).
Technology enablers: AI-assisted diagnosis, medical big data.

Hotspots: elderly care, biopharma, private hospitals, health management.

• Accounts receivable days extended due to reimbursement delays.
• Consistency evaluation & flight inspections increase compliance costs.
• Production line expansion & new drug R&D require huge investment.
• Domestic R&D/sales ratio 3-5% vs global giants >15%.

• Two-invoice system eliminates agency layers, distributors bear sole advance payment duty.
• 2018 distribution net margin 3.9%, inventory turnover 59.6 days.
• Accounts receivable turnover reached 98.7 days, leverage ratio 56.1%.

• Hospital construction/M&A heavy: highest disclosed deal RMB 810 million in 2018.
• Medical insurance reimbursement lag: typically 3-6 months, up to 1 year in some regions.
• Private hospitals face fierce competition & rising operating costs.

• Chain store ratio 50.5% — still room vs US 65%.
• Self-built stores + acquisitions need huge capital; valuation multiples rising (e.g. Xinxing Pharmacy PS 3.8x).
• Classified management increases compliance costs.

Pharma/Device manufacturing 50-60% | Medical institutions 15-25% | Distribution 10-20%.

C-end health insurance & credit medical still early stage.
Financial leasing widespread in devices; supply chain finance focuses on distribution.

Channeling funds to quality big health enterprises.
Industrial finance revitalizes assets, solves expensive & difficult financing.

Modes: direct leasing, sale-leaseback, receivable factoring, reverse factoring, warehouse receipt financing, data-intelligent lending.

Financial institutions monitor real trade background, improve confirmation efficiency, shorten collection cycles.
Upstream gains R&D funds, midstream accelerates cash flow, downstream enhances payment systems.

Whole-chain value maximized.

2018 scale RMB 15.54 billion, growth 27.4%, but penetration in pharmaceutical accounts receivable financing less than 20%.

Total pharma A/R book value RMB 952.67 billion, actual may exceed RMB 1.6 trillion.
Volume-based procurement will boost penetration rapidly.

Reverse factoring & receivable financing account for nearly 100% of activity.
Core enterprises with annual revenue > RMB 5 billion bring stable returns for FIs.
ERP-linked confirmation enables rapid disbursement, cuts chain costs.

Commercial banks hold 35-45% market share (low interest rates + risk control).
Leading distributors (Sinopharm, Shanghai Pharma, China Resources) self-established factoring arms.
Large enterprises (revenue ≥RMB50bn) price sensitive; smaller firms bear 8-12% interest.

1. Resources: state-owned background/government relationships.
2. License: bank, securities, factoring qualifications.
3. Risk control: automated underwriting (“520 model”: 5-min review, 2-sec disbursement, 0 manual intervention). Data modeling as core moat.

Traditional supply chain finance centered around core enterprise offline credit.
Information asymmetry, difficult confirmation, fake bills risk. High labor cost, limited data.

Blockchain + AI + big data: tamper-proof encryption lowers risk cost.
Behavioral & credit risk models improve approval efficiency.
Integrate ERP with pharma information platforms, achieve real-time “three flows integration” (logistics, capital, information).

Core enterprises shift from manufacturing/distribution to terminal service providers (hospitals, pharmacy chains, internet healthcare).
Based on patient consumption data (医保/ commercial insurance/ out-of-pocket), a closed-loop finance emerges.
Banking becomes accessible anywhere — true ecological fusion.

Government: two-invoice system, abolishing device markups.
Enterprises: interconnect hospital ERP, pharma information platforms (Feiyi, Yilian, etc.).
Third-party logistics (JD, SF Express) joining.
“One-invoice” pilot shortens chain further, connecting manufacturers directly with terminals.

By June 2019: served 1,669 industrial chain clients.
Inclusive loan balance RMB 9.139 billion (44% of total loans).
Won first prize of “Hunan 2018 Banking Innovation”.

Leverages shareholders (Tangrenshen, Juewei Food, Yangtianhe Pharmacy) to empower upstream & downstream.

Based on real trade between core enterprise and downstream dealers.
Mobile banking online application, one-year credit line reusable.
Exploring franchisee financing for pharmacy chains.

Step 1: Serve core enterprises via financing & smart advisory.
Step 2: Deep integration expanding to upstream/downstream; collect data on procurement, distribution, sales; build risk models.
Step 3: Accumulate data to reach terminal consumers, establish closed-loop big health finance.

Industrial resources from shareholders (agri/food/pharma).
“520” risk-control efficiency.
Collaboration with pharmacy chains to deepen industrial finance penetration.
Long-term: radiating nationwide from local clients。

Eliminates duplicate pledges and fraudulent bills.
Transaction data on-chain, tamper-proof, lowers due diligence cost.
Enhances transparency and trust in supply chain confirmation.

Credit risk: historical trading data and behavioral profiling.
Network analysis detects potential fraud rings.
Enables FIs to serve long-tail small/mid pharma enterprises, shifting from entity credit to data credit.

Integrate regional health information platforms, reimbursement data, pharmacy retail data for dynamic credit assessment.
Big data can reduce medical expenses by hundreds of billions annually.

API: RMB 384.3B | Chemical preparations: RMB 871.5B | Biologics: RMB 244.3B | TCM: RMB 637.0B | Medical devices: RMB 252.2B. Total large-scale revenue RMB 2.58 trillion.

Private hospitals >20,900, retail pharmacies >454,000 (chain ratio 50.5%), physical exam market around RMB 150B, pharma e-commerce B2C ~RMB 6B.

Medical institutions typically issue bank acceptance bills after 6 months, with medical insurance reimbursement delayed 3-6 months, causing capital strain across the whole chain.

2018 healthcare financings: 695 deals (+52.7% YoY). H1 2019 hotspots: pharma, IVD, AI healthcare. STAR Market listed 16 healthcare companies by end of 2019.

Big Health + Industrial Finance starts from financial leasing, evolves through pharma supply chain finance, and finally reaches ecosystem convergence.
True integration of logistics, capital & information flows is the key.

In the future, through data intelligence and terminal scenario penetration, financial institutions will revitalize industrial chain assets and reduce social medical financing costs.

This white paper was jointly released by iResearch Consulting Group and Hunan Sanxiang Bank. Special thanks for strong support in case studies and insights. Data as of 2019, but the industrial logic and financial paradigms remain highly referential.